|
Agreement adds new analyzer platforms and expands assay menu across key international markets
SAN DIEGO, Feb. 16, 2026 /PRNewswire/ -- QuidelOrtho has entered a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. (Lifotronic Technology Co., Ltd., stock code: 688389), to expand QuidelOrtho's global immunoassay portfolio and accelerate customer access to scalable, high quality, cost-efficient solutions across select markets outside the United States.
The agreement provides QuidelOrtho access to multiple high-throughput and low-to-mid volume immunoassay analyzer platforms, each supported by a broad menu of assays spanning routine and specialty testing. The collaboration is expected to expand QuidelOrtho's immunoassay menu with more than 25 new assays on these systems that are not currently available on the VITROS system, within a total menu of over 70 assays on these new partner platforms.
These additions are planned to increase QuidelOrtho's ability to compete for full-menu tenders and serve a wider range of laboratory settings, from smaller laboratories seeking low-volume solutions to larger, high-throughput environments that require scalable capacity and broad test menus.
Bryan Hanson, Senior Vice President of Global Clinical Laboratory and Transfusion Medicine at QuidelOrtho, said:
"Through our collaboration with Lifotronic Technology, QuidelOrtho will rapidly introduce scalable testing solutions that further advance our long-term innovation strategy in core growth markets. This agreement strengthens our portfolio in markets where assay breadth and cost efficiency are key requirements, while offering customers a broader and more diverse set of solutions."
Mr. Liu Xiancheng, Chairman of Lifotronic Technology, said:
"This strategic partnership with QuidelOrtho marks an important milestone in Lifotronic Technology's global expansion strategy. Going forward, we will work closely with QuidelOrtho, continuing to leverage our in-house R&D strengths to deliver high-value diagnostic solutions that meet real clinical needs for customers worldwide."
The commercial focus will be on Europe, the Middle East, Africa, Mexico, Central America, South America, India, China, Japan, and Asia-Pacific regions. This strategic expansion is planned to support QuidelOrtho's ability to address menu gaps, increase competitiveness in international tenders, and deliver more complete immunoassay solutions to laboratories seeking broader menus and flexible system options.
Source: QuidelOrtho Corporation
About QuidelOrtho
QuidelOrtho (Nasdaq: QDEL) is a global leader in diagnostic solutions, with expertise in clinical chemistry, immunoassay, immunohematology, and molecular diagnostics. The company is dedicated to delivering fast, accurate, and reliable test results to help improve patient outcomes across settings ranging from point-of-care to hospitals, laboratories, and clinics. Building on a strong legacy of innovation, QuidelOrtho partners with healthcare providers to advance diagnostic technologies, connecting insights with solutions to enable informed decision-making and better healthcare delivery.
About Lifotronic Technology
Shenzhen Lifotronic Technology Co., Ltd. (stock code: 688389) is a high-tech medical device company driven by both R&D and commercialization, recognized as a National High-Tech Enterprise and a "Specialized and Innovative Little Giant" enterprise in China. The company focuses on two major business areas: in vitro diagnostics, and therapy and rehabilitation, and is committed to providing innovative, reliable, and cost-effective medical products and solutions to healthcare institutions worldwide. In the IVD field, Lifotronic Technology has built a comprehensive product portfolio covering electrochemiluminescence, HbA1c, and specific protein technologies. In electrochemiluminescence, the company has achieved a full lineup of low-, mid-, and high-throughput immunoassay instruments and reagents. Its products have obtained international certifications such as CE and are distributed globally, continuing to advance precision medicine and global health through technological innovation.
The products referenced in this press release are not currently planned for sale in the United States. These products have not received approval, clearance, or authorization for marketing in any jurisdiction, including the United States, and are not currently marketed or sold. Product launch, sale, and use are subject to obtaining the required regulatory approvals, clearances, or authorizations in each jurisdiction, and there can be no assurance that such approvals will be obtained or obtained within a specific timeframe. Statements regarding future product availability, features, performance, or timing are based on current expectations and are subject to change.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are any statement contained herein that is not strictly historical, including, but not limited to, those relating to the agreement entered into by and between QuidelOrtho and Lifotronic and the transactions contemplated therein, and other future plans, objectives, strategies, expectations and intentions. Such statements are based on the beliefs and expectations of QuidelOrtho's management as of the date of this press release and are subject to significant known and unknown risks and uncertainties. Actual results or outcomes may differ significantly from those set forth or implied in the forward-looking statements. Factors, including those discussed under Part I, Item 1A, "Risk Factors" of QuidelOrtho's Annual Report on Form 10-K for the fiscal year ended December 29, 2024 and subsequent reports filed with the Securities and Exchange Commission, among others, could cause actual results to differ from those set forth or implied in the forward-looking statements. You should not rely on forward-looking statements as predictions of future events because these statements are based on assumptions that may not come true and are speculative by their nature. All forward-looking statements are based on information currently available to QuidelOrtho and speak only as of the date of this press release. QuidelOrtho undertakes no obligation to update any of the forward-looking information or time-sensitive information included in this press release, whether as a result of new information, future events, changed expectations or otherwise, except as required by law.
Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com
Media Contact:
D. Nikki Wheeler
Senior Director, Corporate Communications
media@QuidelOrtho.com
Agreement adds new analyzer platforms and expands assay menu across key international markets
SAN DIEGO, Feb. 16, 2026 /PRNewswire/ -- QuidelOrtho has entered a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. (Lifotronic Technology Co., Ltd., stock code: 688389), to expand QuidelOrtho's global immunoassay portfolio and accelerate customer access to scalable, high quality, cost-efficient solutions across select markets outside the United States.
The agreement provides QuidelOrtho access to multiple high-throughput and low-to-mid volume immunoassay analyzer platforms, each supported by a broad menu of assays spanning routine and specialty testing. The collaboration is expected to expand QuidelOrtho's immunoassay menu with more than 25 new assays on these systems that are not currently available on the VITROS system, within a total menu of over 70 assays on these new partner platforms.
These additions are planned to increase QuidelOrtho's ability to compete for full-menu tenders and serve a wider range of laboratory settings, from smaller laboratories seeking low-volume solutions to larger, high-throughput environments that require scalable capacity and broad test menus.
Bryan Hanson, Senior Vice President of Global Clinical Laboratory and Transfusion Medicine at QuidelOrtho, said:
"Through our collaboration with Lifotronic Technology, QuidelOrtho will rapidly introduce scalable testing solutions that further advance our long-term innovation strategy in core growth markets. This agreement strengthens our portfolio in markets where assay breadth and cost efficiency are key requirements, while offering customers a broader and more diverse set of solutions."
Mr. Liu Xiancheng, Chairman of Lifotronic Technology, said:
"This strategic partnership with QuidelOrtho marks an important milestone in Lifotronic Technology's global expansion strategy. Going forward, we will work closely with QuidelOrtho, continuing to leverage our in-house R&D strengths to deliver high-value diagnostic solutions that meet real clinical needs for customers worldwide."
The commercial focus will be on Europe, the Middle East, Africa, Mexico, Central America, South America, India, China, Japan, and Asia-Pacific regions. This strategic expansion is planned to support QuidelOrtho's ability to address menu gaps, increase competitiveness in international tenders, and deliver more complete immunoassay solutions to laboratories seeking broader menus and flexible system options.
Source: QuidelOrtho Corporation
About QuidelOrtho
QuidelOrtho (Nasdaq: QDEL) is a global leader in diagnostic solutions, with expertise in clinical chemistry, immunoassay, immunohematology, and molecular diagnostics. The company is dedicated to delivering fast, accurate, and reliable test results to help improve patient outcomes across settings ranging from point-of-care to hospitals, laboratories, and clinics. Building on a strong legacy of innovation, QuidelOrtho partners with healthcare providers to advance diagnostic technologies, connecting insights with solutions to enable informed decision-making and better healthcare delivery.
About Lifotronic Technology
Shenzhen Lifotronic Technology Co., Ltd. (stock code: 688389) is a high-tech medical device company driven by both R&D and commercialization, recognized as a National High-Tech Enterprise and a "Specialized and Innovative Little Giant" enterprise in China. The company focuses on two major business areas: in vitro diagnostics, and therapy and rehabilitation, and is committed to providing innovative, reliable, and cost-effective medical products and solutions to healthcare institutions worldwide. In the IVD field, Lifotronic Technology has built a comprehensive product portfolio covering electrochemiluminescence, HbA1c, and specific protein technologies. In electrochemiluminescence, the company has achieved a full lineup of low-, mid-, and high-throughput immunoassay instruments and reagents. Its products have obtained international certifications such as CE and are distributed globally, continuing to advance precision medicine and global health through technological innovation.
The products referenced in this press release are not currently planned for sale in the United States. These products have not received approval, clearance, or authorization for marketing in any jurisdiction, including the United States, and are not currently marketed or sold. Product launch, sale, and use are subject to obtaining the required regulatory approvals, clearances, or authorizations in each jurisdiction, and there can be no assurance that such approvals will be obtained or obtained within a specific timeframe. Statements regarding future product availability, features, performance, or timing are based on current expectations and are subject to change.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are any statement contained herein that is not strictly historical, including, but not limited to, those relating to the agreement entered into by and between QuidelOrtho and Lifotronic and the transactions contemplated therein, and other future plans, objectives, strategies, expectations and intentions. Such statements are based on the beliefs and expectations of QuidelOrtho's management as of the date of this press release and are subject to significant known and unknown risks and uncertainties. Actual results or outcomes may differ significantly from those set forth or implied in the forward-looking statements. Factors, including those discussed under Part I, Item 1A, "Risk Factors" of QuidelOrtho's Annual Report on Form 10-K for the fiscal year ended December 29, 2024 and subsequent reports filed with the Securities and Exchange Commission, among others, could cause actual results to differ from those set forth or implied in the forward-looking statements. You should not rely on forward-looking statements as predictions of future events because these statements are based on assumptions that may not come true and are speculative by their nature. All forward-looking statements are based on information currently available to QuidelOrtho and speak only as of the date of this press release. QuidelOrtho undertakes no obligation to update any of the forward-looking information or time-sensitive information included in this press release, whether as a result of new information, future events, changed expectations or otherwise, except as required by law.
Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com
Media Contact:
D. Nikki Wheeler
Senior Director, Corporate Communications
media@QuidelOrtho.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
QuidelOrtho Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio
QuidelOrtho Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio
QuidelOrtho Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio
News Summary:
- Relativity integrates the Claude Compliance API to enable the collection of Claude Enterprise activity in RelativityOne.
- RelativityOne enables native collection from ChatGPT Enterprise, Gemini Enterprise and now Claude Enterprise.
- This follows Relativity's participation in Anthropic's Claude for the legal industry launch, where Anthropic introduced an MCP integration that enables legal data and technology teams to use natural language to orchestrate administrative workflows in RelativityOne.
CHICAGO, May 22, 2026 /PRNewswire/ -- Relativity, a legal data intelligence company, today announced an integration with the Claude Compliance API, bringing Claude Enterprise activity into RelativityOne, its extensible AI platform for legal work. With this new integration, RelativityOne supports native collection from ChatGPT Enterprise, Gemini Enterprise and now Claude Enterprise.
Adding Claude Enterprise as a Collect in RelativityOne data source enables legal data and technology teams, as well as security and compliance teams, to seamlessly collect activity logs and conversation content. This integration builds on Relativity's participation in Anthropic's Claude for the legal industry launch last week, where it introduced a Model Context Protocol (MCP) integration connecting RelativityOne with Claude.ai, Claude Cowork and Claude Code. Together, these integrations support both the collection of AI-related data and the management of matters in RelativityOne.
"Whether teams are using RelativityOne to collect Claude Enterprise data or using Claude to stand up RelativityOne workspaces and manage administrative workflows in RelativityOne through natural language, it all comes back to one goal: helping legal data and technology teams move from data to insight to action faster and with more confidence," said Chris Brown, Chief Product Officer at Relativity. "aiR and RelativityOne power that journey—analyzing documents, identifying privilege, surfacing case strategy and driving workflows to completion—all on one platform. As enterprise AI generates an entirely new class of business data, RelativityOne is the platform built to govern, analyze and act on it."
RelativityOne, the foundation for modern legal data at scale
According to a recent Gallup survey, half of employed American adults report they use AI in their role. As generative AI becomes embedded in everyday work, it is also creating a new and rapidly growing class of enterprise data, any of which can become legal data. Organizations need visibility into how generative AI tools are being used, along with the ability to collect that data within a highly secure and scalable platform designed for the massive volume and complexity of today's enterprise data. Bringing Claude Enterprise conversations into RelativityOne places this new class of human-to-AI content within the platform designed to handle the breadth and magnitude of modern legal work.
Collect and process Claude Enterprise data in RelativityOne
The integration with the Claude Compliance API provides organizations with improved transparency into custodian or entity activity, including activity logs such as user logins, administrative actions and configuration changes, as well as conversation content like chats, uploaded files, and projects, all retrievable via dedicated read endpoints.
Relativity customers and partners can collect Claude Enterprise data directly from the source and process it into a reviewable format within RelativityOne. Once that data is in RelativityOne, teams can apply purpose-built AI for legal outcomes, Relativity aiR, to analyze that data alongside other enterprise data, maintaining context across AI-driven workflows while supporting governance, transparency and defensibility.
Bringing intelligent orchestration to where legal work gets done
The MCP integration adds a conversational orchestration layer on top of RelativityOne, letting system administrators—litigation support teams, legal operations, service providers and developers—stand up new matters, align workspaces to the structure of their data, and manage access and workflows through natural language. By reducing the administrative lift required to provision workspaces, understand data structures, and manage users, teams can move from trigger event to analysis faster, while decisions can still shape outcomes. Additionally, downstream litigator workflows including chronologies, deposition preparation and claim chart creation are executed within RelativityOne.
It also delivers real-time visibility into operations, surfacing usage patterns, reinforcing best practices and supporting more informed decisions across matters, clients and practice groups. That same visibility strengthens governance: teams can audit access, manage matter lifecycles and maintain a defensible posture with less risk of inadvertent disclosure.
RelativityOne has long been a platform meant to be extended through open APIs, its app marketplace, and a partner ecosystem that customers have shaped to their work. This integration further empowers Relativity's user community to orchestrate their RelativityOne environments, streamline operational tasks and ultimately dedicate more time to strategic work.
Claude provides the natural-language orchestration surface, while RelativityOne remains the system of record and system of action, where sensitive data is governed and the work is performed. Relativity aiR—purpose-built for the privilege calls, responsiveness determinations and case-strategy reasoning that legal work requires—is the AI engine for substantive legal analysis, grounded in the evidence itself and governed by Relativity's platform controls.
Learn more and connect with the Relativity team at RelFest London, taking place June 15-16.
About Relativity
Relativity is a leading legal data intelligence company that builds technology to help users organize data, discover the truth, and act on it. Its extensible, AI-powered cloud platform, RelativityOne, transforms complex data into actionable insights at massive scale for litigation, investigations, regulatory inquiries, data breach responses, and other legal use cases. The world's largest law firms and corporations, government agencies, and a robust network of channel partners rely on Relativity's legal AI software to securely surface and manage the most relevant and impactful information in their matters. The company also expands access to technology by providing its platform at no cost to academic institutions through its Relativity Academic program and to organizations supporting pro bono legal work through its Justice for Change initiative.
CONTACT: PR@relativity.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Relativity Adds Collection of Claude Enterprise Data with Claude Compliance API Integration
